MedTech Companies Focus on Data Quality and Site Collaboration for Clinical Trials

MedTech Companies Prioritize Collaboration and Data Quality

In today's rapidly evolving medical technology sector, collaboration between clinical teams and research sites has become paramount. According to the recent findings from the 2025 Veeva MedTech Clinical Benchmark, a significant trend has emerged: nearly 70% of medtech companies are recognizing the need to reduce manual processes as a key priority for effective collaboration with clinical research sites.

The report, released by Veeva Systems, indicates that these companies want to streamline their workflows to accomplish several goals: minimizing manual interventions, enhancing study quality, and increasing visibility and oversight. Specifically, survey responses revealed that 68% of organizations prioritize the reduction of manual processes, with 56% focused on improving study quality, and 55% aiming for better visibility and governance.

Challenges in Clinical Trial Management

While these goals are clear, medtech organizations are still grappling with significant challenges. The benchmark indicates that the timely input and quality of data, document sharing, and compliance oversight stand out as some of the most substantial hurdles in managing research centers. Alarmingly, only 14% of medtech companies with revenues exceeding $1 billion possess effective collaboration tools among research sites. This gap highlights the industry’s struggle as it aims to enhance trial efficiencies and accelerate study timelines.

The reliance on manual processes presents risks that organizations cannot afford to overlook. According to the findings, 32% of respondents cited manual processes as the biggest risk factor. Other notable challenges included compliance with global clinical trial regulations (18%) and preparedness for audits (18%). These issues could potentially inflate operational costs and cause significant delays in trials.

Optimizing Clinical Processes

Despite these challenges, there is a growing trend among companies to implement optimization strategies. Approximately 58% of medtech firms plan to prioritize data collection and cleansing in the upcoming year. By refining their data collection processes, organizations can devote more time to high-value trial operations rather than data reconciliation, thereby ensuring that clinical trial integrity remains intact.

Another exciting development is the nascent adoption of Artificial Intelligence (AI) and Machine Learning (ML) technologies within the industry. About 72% of the surveyed medtech companies are keen on investing in infrastructure for AI and ML solutions, working towards harmonizing their existing systems and standardizing data to better prepare for advanced analytics. This investment demonstrates a commitment to innovation that can significantly impact trial outcomes and patient care.

As Kevin Liang, Vice President of Clinical Strategy for Veeva MedTech, aptly noted, “The medtech industry is pursuing initiatives to enhance clinical processes, inter-site collaboration, and data quality against a backdrop of economic pressures and new regulations.” The report outcomes indicate that companies in this domain are taking substantial steps to ensure data integrity, boost operational efficiency, and facilitate connected processes among stakeholders to bring new technologies to patients more swiftly.

The 2025 Veeva MedTech Clinical Benchmark report is based on a survey of over 100 clinical professionals from medical device and diagnostic firms. By providing a comprehensive analysis of the current state of clinical trials in the medtech sphere, the report sheds light on how teams are modernizing their operational frameworks.

For further insights, the full report can be accessed here.

About Veeva MedTech

Veeva MedTech specializes in assisting medical device and diagnostic companies in optimizing the development and marketing of their products, aiming to deliver them to patients promptly and efficiently. Its offerings include applications that enhance clinical, regulatory, quality, commercial, and medical operations. For more information, visit veeva.com/medtech.

About Veeva Systems

Veeva is a global leader in cloud-based software solutions for life sciences. With a commitment to innovation and product excellence, Veeva serves over 1,000 customers, ranging from the largest bio-pharmaceutical firms to emerging biotech companies. As a Public Benefit Corporation, Veeva emphasizes a balance of interests among all stakeholders, including clients, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.